Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × CLR1404 × Clear all

Phase

Phase 1 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Temozolomide 56 Bevacizumab 37 Radiotherapy 19 Magnetic Resonance Spectroscopy 18 Irinotecan 15 Specimen Handling 9 Carmustine 9 Carboplatin 9 olaparib 6 X-Rays 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Cyclophosphamide 6 Thalidomide 5 Nuclear Medicine Department, Hospital 5 Biopsy 5 trametinib 4 pembrolizumab 4 Radiation 4 Nivolumab 4 Lomustine 4 Everolimus 4 Cisplatin 4 Aminolevulinic Acid 4 sargramostim 3 poly ICLC 3 ivosidenib 3 fluorodopa F 18 3 erdafitinib 3 dabrafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01778088 2014-02-25

Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

Cellectar Biosciences, Inc.

Phase 2 Withdrawn

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡